Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.37 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21483766 | 0.78 | JAK2 (0.41) | GPR52PARP11PARP1PARP10PDPK1 | |
| SCHEMBL17256724 | 0.74 | GPR52 (0.42) | GPR52PARP11PARP1PARP10PDPK1 | |
| SCHEMBL17256683 | 0.70 | GPR52 (0.44) | GPR52PARP11PARP1PARP10MAPKAPK2 | |
| SCHEMBL21623937 | 0.67 | BPTF (0.39) | GPR52PARP11PARP1PARP10PDPK1 | |
| SCHEMBL21987967 | 0.66 | PARP10 (0.41) | GPR52PARP11PARP1PARP10PDPK1 | |
| SCHEMBL4716078 | 0.66 | GPR52 (0.54) | GPR52PARP11PARP1PARP10MAPKAPK2 | |
| SCHEMBL21987940 | 0.66 | PKN1 (0.40) | GPR52PARP11PARP1PARP10PDPK1 | |
| SCHEMBL27650487 | 0.64 | MAPT (0.43) | PARP1NCF1 | |
| SCHEMBL300231 | 0.62 | GRM5 (0.44) | PARP11PARP1PARP10PDPK1PDE4B | |
| SCHEMBL22216242 | 0.62 | PKN1 (0.41) | GPR52PARP11PARP1PARP10PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2019197549-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | CDK1, CDK2, CDK15 | GPR52 3457/4885PARP11 659/4885PARP1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.